Business Wire

IL-APTARGROUP

26.5.2021 14:32:09 CEST | Business Wire | Press release

Share
Aptar Introduces a Fully Recyclable Mono-Material Pump

AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, announces the launch of the company’s first fully recyclable mono-material pump for the beauty and personal care industries, called Future.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210526005198/en/

Certified and Sustainable by Design

In order to facilitate recycling, Future was designed using polyethylene (PE) mono-material only. Future is certified by Cyclos-HTP, the institute for Recyclability and Product Responsibility * . The innovation is also recognized “A” by RecyClass – a comprehensive cross-industry initiative that works to establish a harmonized recycling approach and traceability in Europe*.

“Today we are pleased to launch our latest sustainable innovation, Future, a game changing dispensing solution. Following more than two years of design, engineering and testing, I am very proud of our team’s mono-material design and it truly reflects our commitment to a more circular economy,” said Marc Prieur, President, Aptar Beauty + Home.

In developing the concept for Future, Aptar’s experts turned to recognized eco-design principles, which call for plastic dispensing products to be made from a mono-material to facilitate the recycling process. Traditional pumps may contain different materials, including metal components that can in some cases complicate the recycling process. Because the Future pump is made from PE only, it also aligns with the most common materials used to make bottles – PE and PET. Therefore, the complete packaging, including pump and bottle, are more easily recycled*.

Christophe Marie, Product Sustainability Director, Aptar, explains, “The ideal situation for the complete value chain is to have mono-material packaging where the container, the closure or dispensing system is made from the same material family. This was the big challenge our innovation team overcame with the development of Future.”

*Subject to local recyclability facilities and fully recyclable with PET and PE bottles.

RecyClass recognition applies for an undecorated clear or white pump.

Future is also available using post-consumer resin (PCR). Aptar Beauty + Home proudly obtained an International Sustainability & Carbon Certification (ISCC) for its European production.

“Our ultimate goal was to have the final consumer be able to take their body lotion, shampoo or shower gel and easily put the empty packaging in their recycling bin. This way, it enters a circular life cycle and can be turned into another product,” explained Sabine Bouillet-Lubot, Global Strategic Marketing Director, Aptar Beauty + Home.

E-Commerce Capable & Eco-Design

The Future pump combines the best eco-design principles with cutting-edge innovation. A stand-out feature of the Future pump’s innovative design is an incorporated on/off locking system and a 360° degree actuator. This modern take on closure design also renders Future compliant with the rigorous ISTA 6-Amazon protocol**. Designed for e-commerce, Future’s ISTA 6 compliance ensures that the pump withstands the risks associated with transport and distribution network pressures as well as necessitates less protective carton and paper packaging.

**Subject to final tests conducted by a brand’s bottle choice.

Sustainability at Aptar

Aptar believes that the packaging industry must move beyond the make, use, dispose behaviors of the past and actively work toward a circular economy. By circulating used plastic and packaging, we keep it in the economy and out of the environment. Therefore, reducing the quantity of plastic needed, using recycled materials and developing reuse models. Our vision is to design products and processes with people and the planet in mind and we are focusing our activities on three mains areas for sustainability: recycled materials, recyclability and reusability. Collaboration is essential to achieving a more circular economy, so we work with partners, suppliers and customers who share our vision. As a member of the Ellen MacArthur Foundation’s New Plastics Economy Global Commitment, this innovation highlights our pledge to reduce environmental impact and support the Foundation’s vision for a circular economy. We are working hard towards our 2025 goal to have all of our packaging 100% reusable, recyclable or compostable for our dispensing solutions for the beauty, personal care, home care and food and beverage markets.

Aptar to Present at the ChangeNow 2021 Global Summit

Aptar’s innovative dispensing solution will be introduced live at the ChangeNOW 2021 Global Summit on May 27th. As a proud supporting partner of ChangeNOW, Aptar’s Vice President of Global Sustainability, Beth Holland, will be a featured guest speaker during the circular economy panel discussion.

About Aptar

Aptar is a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com .

This press release contains forward-looking statements. Expressions or future or conditional verbs such as “will” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-Ks and Form 10-Qs. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release

Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co

Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release

Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents

Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release

Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and

LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release

The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o

Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release

Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye